International Addiction Conference | Stapleford Berlin 2006

<body onload="window.defaultStatus=' --- Suchtmedizinische Schwerpunktpraxen Berlin ---'"> <a href="conference_2006/addiction_conference_2006_berlin.html">home</a> <a href="conference_2006/addiction_conference_2006_conf.html">conference</a> <a href="conference_2006/addiction_conference_2006_prog.html">program + speakers</a> <a href="conference_2006/addiction_conference_2006_cont.html">application + contact</a> <a href="conference_2006/addiction_conference_2006_hote.html">hotel accomodation</a> <a href="conference_2006/addiction_conference_2006_hist.html">history</a> <a href="conference_2006/addiction_conference_2006_link.html">links</a> <a href="conference_2006/addiction_conference_2006_impr.html">disclaimer + impressum</a> <p> <h1>3rd Berlin Stapleford International Addiction Conference on: Latest developments in effective medical treatments for addiction. Hotel Excelsior, Hardenbergstr. 14, 10623 Berlin, Germany Weekend of March 18-20th 2006</h1> <p>Use this page to navigate your way to information about speakers, conference themes, how to register, where to stay, how to submit an abstract and some of the many interesting things to see and do in the exciting city of Berlin.</p> <p>main topics: 1. Anaesthesia vs. light sedation in ROD/RAI (Rapid Opiate Detoxification/Rapid Antagonist Induction) 2. Update on naltrexone implants and depot injections in alcoholism and opiate dependence. 3. Clinical experience with rapid benzodiazepine detoxification using flumazenil 4. Depot buprenorphine and slow-release morphine as alternatives to methadone for opioid maintenance 5. Disulfiram vs. naltrexone and acamprosate in alcohol abuse 6. Vaccines and agonist maintenance for cocaine/ amphetamine dependence; Cannabis antagonists </p> </p> <p>conference:</p> <p>This is the 8th Stapleford international addiction conference and the 3rd to be held in Berlin. Endorsed by: The University of Nijmegen The Free University of Brussels ISAM – the International Society of Addiction Medicine Deutsche Gesellschaft für Suchtmedizin (DGS) As always, the emphasis is on medical or pharmacological interventions but that’s not because we don’t think psychological or social interventions are important. It’s obvious that medical treatments are usually just one component of a comprehensive treatment package and it’s equally obvious that many patients need psycho-social help even if their pharmacological addiction is halted or controlled. It’s simply that there are many conferences largely or totally concerned with psycho-social treatments and very few that are concerned primarily with medical ones. And as always, our focus is on treatments, techniques and research that seem to offer something that is both useful and relatively new orthat involve important arguments about how best to apply these treatments in real life. </p> <p>conference program + confirmed speakers:</p> <p>1. Anaesthesia vs. light sedation in ROD/RAI (Rapid Opiate Detoxification/Rapid Antagonist Induction) H. Kleber, New York; Cor de Jong, Nijmegen; Catherine de Jong, Amsterdam; J. Currie, P. Cox, Sydney; G. O’Neil, Perth; N. Maksoud, Cairo. 2. Update on naltrexone implants and depot injections in alcoholism and opiate dependence. H. Kleber, New York; G. Hulse, G. O’Neill, Perth; A. Startosa (for Dr J Volpicelli) Philadelphia; L. Partecke, Berlin. 3. Clinical experience with rapid benzodiazepine detoxification using flumazenil J. Currie, Sydney; G. O’Neill, Perth. 4. Depot buprenorphine and slow-release morphine as alternatives to methadone for opioid maintenance G. Fischer, Vienna; n.n. from Titan Pharmaceutical. 5. Disulfiram vs. naltrexone and acamprosate in alcohol abuse H. Alho, Helsinki; (possibly first presentation of the Helsinki randomised trial results.) A. de Sousa, Mumbai; M. Faiman, Kansas; J. Chick, Edinburgh; H. Ehrenreich, Göttingen; C. Brewer, London. 6. Vaccines and agonist maintenance for cocaine/ amphetamine dependence; Cannabis antagonists n. n. n. n.</p> <p>application + contact:</p> <p>information, registration, abstract submissions etc. at: mail@stapleford-berlin2006.de registraion form: download registration form (.pdf) Please print form and send to fax: +44 (0)20. 77 30 34 09 (Stapleford Centre, London) Resentations are invited on the above topics or closely related issues and poster facilities will be available. Submission deadline: January 13th 2006 Dr. Linda Partecke, Berlin Dr. Colin Brewer, London email: mail@stapleford-berlin2006.de fax: +44 (0)20. 77 30 34 09 (Stapleford Centre, London) </p> <p>hotel accomodation:</p> <p>Berlin Excelsior with special rates (129€ double | 119€ single) Hotel Astoria (50m around the corner of Hotel Excelsior) (99€ double | 89€ single) or hotel of your choice. Berlin Excelsior Hardenbergstr. 14 | 10623 Berlin <a href="http://www.hotel-excelsior.de" target="_blank">www.hotel-excelsior.de</a> Reservations: phone: +49 (0)30. 3155 – 22 fax: +49 (0)30. 3155-1053 email: reservations@hotel-excelsior.de Hotel Astoria Fasanenstr. 2 | 10623 Berlin <a href="http://www.astoriahotels.de" target="_blank">www.astoriahotels.de</a> Reservations: phone: +49 (0)30. 2134067 fax: +49 (0)30. 213 5027 email: astoriahotel@t-online.de</p> <p>history:</p> <p>In many clinics for abusers of alcohol, heroin and other drugs, there have been few really significant changes in treatment or outcome since the introduction of disulfiram in 1948 and methadone maintenance in 1965. In several countries, even methadone maintenance is not allowed. This situation is changing but still quite slowly and is in total contrast to the rest of medicine, where big changes and many improvements in outcome have occurred. One major reason for this contrast is that promising technologies and medications are quickly evaluated and often universally adopted in general medicine and surgery but not in addiction treatment. Especially in the US, addiction is still widely seen as a moral or ‘spiritual’ problem that requires exclusively spiritual and/ or psychosocial interventions. This attitude does not co-exist easily with medical treatments. That is why, while recognising the importance of specific psychosocial interventions for many patients, the eight Stapleford conferences since 1989 have concentrated on how to get the best out of existing pharmacological interventions and on promising developments in pharmacotherapy and technology. Even in the three years since the last conference in Nijmegen, there have been some important developments. First, the largely unfulfilled potential of oral naltrexone as a treatment for both opiate and alcohol abuse, because of poor compliance, is now being increasingly achieved by the increasing use of implanted or depot naltrexone. The expected release of the first licensed depot preparation in mid-2006 represents real progress, albeit one for which the necessary technology had existed for decades and had been successfully used in other fields. Secondly, it is now clear that the very low rates of successful opiate detoxification and naltrexone induction using conventional techniques (typically 20-30% at most) can only be significantly improved at present by techniques that complete the process of withdrawal and induction within 24 hours, or at most within a few days. The argument has now shifted to the best methods for achieving this rapid transfer to naltrexone and in particular, the levels of sedation or anaesthesia that are necessary, and the risks that are acceptable, to maximise success and minimise distress and dropout. In all of these areas, the leading researchers and commentators will be presenting their findings. At the 1996 Stapleford conference in London, Prof. Gilberto Gerra presented a paper on rapid benzodiazepine detoxification using the antagonist/inverse agonist flumazeni. This novel idea was taken up by some of those present and two Australian clinicians will be presenting data on several hundred procedures, showing that the technique is simple, effective, not distressing and apparently very safe. Certainly much safer than many people thought it could be. In conjunction with long-acting implants of flumazenil, this looks like being the next big treatment revolution in addiction. Many people hope that the imminent release of depot naltrexone will bring about significant improvements in the effectiveness of alcoholism treatment. We hope so too, but speakers at previous Stapleford conferences have noted that the evidence-base for supervised disulfiram treatment is also strong. In 2004, the prestigious British journal ‘Addiction’ finally conceded that this was true and that disulfiram had for long been undervalued or worse. Recent controlled studies have examined the relative effectiveness of oral disulfiram, naltrexone and acamprosate and the latest results will be presented here. They confirm that disulfiram still has an important role in treatment. Finally, we will discuss clinically important new techniques in a few other areas of treatment, including opiate maintenance - and possibly treatments for cocainism and surgery for resistant obesity as well. We look forward to welcoming you to the exciting and culture-rich city of Berlin and we hope you will return home after the conference feeling that addiction medicine need not remain stuck in a 1960s time-warp. Dr. Linda Partecke and Dr. Colin Brewer, November 2005</p> <p>links:</p> <p>Stapleford Centre, London <a href="http://www.staplefordcentre.co.uk" target="_blank">www.staplefordcentre.co.uk</a> Dr. Linda Partecke, Berlin <a href="http://www.anaesthesie-partecke.de" target="_blank">www.anaesthesie-partecke.de</a> Radboud Universiteit Nijmegen <a href="http://www.ru.nl" target="_blank">www.ru.nl</a> Universite Libre de Bruxelles <a href="http://www.ulb.be" target="_blank">www.ulb.be</a> ISAM – International Society of Addiction Medicine <a href="http://www.isamweb.com" target="_blank">www.isamweb.com</a> Deutsche Gesellschaft für Suchtmedizin (DGS) <a href="http://www.dgsuchtmedizin.de" target="_blank">www.dgsuchtmedizin.de</a> Suchtmedizinische Schwerpunktpraxen Berlin <a href="http://www.ambulante-suchtmedizin.de" target="_blank">www.ambulante-suchtmedizin.de</a> Berlin information: www.berlin.de www.berlin-online.de www.berlin-airport.de</p> <p>disclaimer + impressum</p> <p>copyright All material on this site is copyright ©2005 Stapleford-Berlin2006.de, except where specifically stated otherwise. Visitors may read, view, print and download the material for their personal, non-commercial use only. Visitors may not recopy or further distribute, sell, publish or transmit any part of the material by any means (electronic or not). links to other sites: Certain links in this site will lead you to sites which are not under the control of Stapleford-berlin2006. When you activate any of these, you will leave this website. We accept no responsibility or liability for the contents of any site to which a hypertext link exists and gives no representation or warranty (express or implied) as to the information on such sites. responsibility (verantwortlich nach TDG): Dr. Linda Partecke, Berlin Maierottostr. 5 | 10719 Berlin fax: +49 (0)30. 88709459 mob: +49 (0)172. 839193 Dr. Colin Brewer, London fax: +44 (0)20. 77303409 (Stapleford Centre, London) email: mail@stapleford-berlin2006.de <a href="http://www.d-form.com" target="_blank">concept & webdesign: Raphael T. Deinert, [d.form] Berlin www.d-form.com</a></p> </body>